Portfolio Company Vedanta Announces Promising Phase 2 Trial Results

By Sal Daher, CFA

Vedanta Biosciences announced October 5th, 2021 that its experimental therapy VE303 reduces the likelihood of recurrence of C. diff. by more than 80%. BARDA exercises $23.8 million to fund Phase 3 clinical trials starting in 2022.

Heres a link to the press release: https://www.businesswire.com/news/home/20211005005154/en/PureTech-Founded-Entity-Vedanta-Announces-Positive-Topline-Phase-2-Data-for-VE303-in-High-Risk-C.-difficile-Infection-and-Exercise-of-23.8-Million-Option-by-BARDA